4D Molecular Therapeutics stockholders elect David Kirn as Class I director and ratify PwC as auditor

4D Molecular Therapeutics, Inc.

David Kirn, M.D. elected as Class I director with 35,630,613 votes for, 7,849,441 withheld, and 1,574,659 broker non-votes.
Ratification of PricewaterhouseCoopers LLP as independent auditor for FY2024: 45,032,000 for, 21,052 against, 1,661 abstain.
Annual Meeting held on May 21, 2024; 45,054,713 of 51,157,472 outstanding shares voted.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.